Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 19;133(24):2998-3000.
doi: 10.1097/CM9.0000000000001232.

Time to relapse after treatment withdrawal for different biologics used to treat plaque psoriasis

Xiao-Yu Wang  1 , Chun-Lei Zhang, Wen-Hui Wang
Affiliations

Time to relapse after treatment withdrawal for different biologics used to treat plaque psoriasis

Xiao-Yu Wang et al. Chin Med J (Engl). .
No abstract available

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Comparison of the median time to relapse among different biologics. (A) Head-to-head comparison of time to relapse (PGA ≥ 3) between etanercept and ustekinumab (left); head-to-head comparison of time to relapse (initiation of new systemic treatment) between secukinumab and guselkumab (right). (B) Time to relapse (loss of PASI 50) in individual studies. (C) Time to relapse (PGA ≥ 3) in individual studies. IL: Interleukin; PASI: Psoriasis Area and Severity Index; PGA: Physician's Global Assessment score; TNF: Tumor necrosis factor.
See this image and copyright information in PMC

References

    1. Gordon KB, Gottlieb AB, Leonardi CL, Elewski BE, Wang A, Jahreis A, et al. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatolog Treat 2006; 17:9–17. doi: 10.1080/09546630500472838. - PubMed
    1. Bellinato F, Girolomoni G, Gisondi P. Relapse of psoriasis in patients who asked to discontinue etanercept after achieving a stable clinical remission. Br J Dermatol 2019; 181:1319–1320. doi: 10.1111/bjd.18225. - PubMed
    1. Efficacy and safety of infliximab in long-term treatment of plaque-type psoriasis: A comparative retrospective study on two different (continuous vs. relapse related) regimens. J Am Acad Dermatol 2007; 56:B190.doi: 10.1016/j.jaad.2006.10.866.
    1. Papp K, Crowley J, Ortonne JP, Leu J, Okun M, Gupta SR, et al. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Br J Dermatol 2011; 164:434–441. doi: 10.1111/j.1365-2133.2010.10139.x. - PubMed
    1. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362:118–128. doi: 10.1056/NEJMoa0810652. - PubMed